

Alberto Zanchetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9477745/publications.pdf>

Version: 2024-02-01

478
papers

72,856
citations

2544

96
h-index

568

263
g-index

493
all docs

493
docs citations

493
times ranked

39903
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	2.2	6,826
2	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2013, 34, 2159-2219.	2.2	5,681
3	Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. <i>Lancet, The</i> , 1998, 351, 1755-1762.	13.7	5,398
4	2007 Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1105-1187.	0.5	4,778
5	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2013, 31, 1281-1357.	0.5	4,251
6	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. <i>Lancet, The</i> , 2009, 373, 1849-1860.	13.7	3,100
7	Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. <i>Lancet, The</i> , 1997, 350, 757-764.	13.7	2,841
8	Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. <i>Lancet, The</i> , 2004, 363, 2022-2031.	13.7	2,422
9	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1953-2041.	0.5	2,129
10	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.	2.2	1,617
11	The Study on Cognition and Prognosis in the Elderly (SCOPE). <i>Journal of Hypertension</i> , 2003, 21, 875-886.	0.5	1,251
12	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009, 27, 2121-2158.	0.5	1,236
13	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1751-1762.	0.5	1,152
14	European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. <i>Journal of Hypertension</i> , 2013, 31, 1731-1768.	0.5	1,124
15	2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. <i>Journal of Hypertension</i> , 2016, 34, 1887-1920.	0.5	898
16	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2013, 31, 1925-1938.	0.5	789
17	European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. <i>Journal of Hypertension</i> , 2014, 32, 1359-1366.	0.5	758
18	Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. <i>Lancet, The</i> , 2012, 379, 1602-1612.	13.7	743

#	ARTICLE	IF	CITATIONS
19	European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. <i>Journal of Hypertension</i> , 2008, 26, 1505-1526.	0.5	707
20	Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2073.	7.4	646
21	Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2009, 27, 1719-1742.	0.5	620
22	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2014, 23, 3-16.	1.5	565
23	Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. <i>Lancet, The</i> , 2004, 363, 2049-2051.	13.7	540
24	Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis. <i>Circulation</i> , 2002, 106, 2422-2427.	1.6	503
25	Ambulatory Blood Pressure Is Superior to Clinic Blood Pressure in Predicting Treatment-Induced Regression of Left Ventricular Hypertrophy. <i>Circulation</i> , 1997, 95, 1464-1470.	1.6	502
26	Alterations of Cardiac Structure in Patients With Isolated Office, Ambulatory, or Home Hypertension. <i>Circulation</i> , 2001, 104, 1385-1392.	1.6	444
27	Ambulatory blood pressure normality. <i>Journal of Hypertension</i> , 1995, 13, 1377-1390.	0.5	433
28	Renal Function and Intensive Lowering of Blood Pressure in Hypertensive Participants of the Hypertension Optimal Treatment (HOT) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 218-225.	6.1	415
29	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2013, 22, 193-278.	1.5	355
30	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Blood Pressure</i> , 2009, 18, 308-347.	1.5	351
31	The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. <i>Journal of Hypertension</i> , 2005, 23, 2157-2172.	0.5	326
32	Genome-Wide Association Study of Blood Pressure Extremes Identifies Variant near UMOD Associated with Hypertension. <i>PLoS Genetics</i> , 2010, 6, e1001177.	3.5	312
33	2007 ESH/ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2007, 16, 135-232.	1.5	292
34	Blood-pressure control in the hypertensive population. <i>Lancet, The</i> , 1997, 349, 454-457.	13.7	280
35	Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. <i>Journal of Hypertension</i> , 2014, 32, 2285-2295.	0.5	267
36	Risk factors associated with alterations in carotid intima-media thickness in hypertension. <i>Journal of Hypertension</i> , 1998, 16, 949-961.	0.5	260

#	ARTICLE	IF	CITATIONS
37	Effects of blood pressure lowering on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 613-622.	0.5	254
38	Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). <i>Journal of Hypertension</i> , 2001, 19, 1981-1989.	0.5	246
39	When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. <i>Journal of Hypertension</i> , 2009, 27, 923-934.	0.5	243
40	High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. <i>Journal of Hypertension</i> , 2001, 19, 2063-2070.	0.5	242
41	New-onset diabetes and antihypertensive drugs. <i>Journal of Hypertension</i> , 2006, 24, 3-10.	0.5	242
42	Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study. <i>Hypertension</i> , 2007, 49, 40-47.	2.7	221
43	Effects of blood pressure lowering on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2015, 33, 195-211.	0.5	221
44	The Verapamil in Hypertension and Atherosclerosis Study (VHAS). <i>Journal of Hypertension</i> , 1998, 16, 1667-1676.	0.5	216
45	Guidelines for the use of self-blood pressure monitoring. <i>Journal of Hypertension</i> , 2000, 18, 493-508.	0.5	200
46	Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. <i>Journal of Hypertension</i> , 2008, 26, 403-411.	0.5	190
47	The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. <i>Journal of Hypertension</i> , 2011, 29, 4-16.	0.5	189
48	Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. <i>Hypertension</i> , 2001, 37, 12-18.	2.7	177
49	Seasonal variations in home and ambulatory blood pressure in the PAMELA population. <i>Journal of Hypertension</i> , 1998, 16, 1585-1592.	0.5	175
50	Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. <i>Journal of Hypertension</i> , 2006, 24, 603-610.	0.5	175
51	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2017, 35, 922-944.	0.5	173
52	Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. <i>Journal of Hypertension</i> , 2004, 22, 847-857.	0.5	172
53	Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2010, 56, 956-965.	2.8	171
54	Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure. <i>Journal of Hypertension</i> , 2004, 22, 273-280.	0.5	169

#	ARTICLE	IF	CITATIONS
55	Metabolic syndrome and target organ damage in untreated essential hypertensives. <i>Journal of Hypertension</i> , 2004, 22, 1991-1998.	0.5	167
56	Effect of Baseline Cognitive Function and Antihypertensive Treatment on Cognitive and Cardiovascular Outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). <i>American Journal of Hypertension</i> , 2005, 18, 1052-1059.	2.0	161
57	Antihypertensive Therapy: How to Evaluate the Benefits. <i>American Journal of Cardiology</i> , 1997, 79, 3-8.	1.6	158
58	Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5. <i>JAMA Internal Medicine</i> , 2017, 177, 1498.	5.1	158
59	Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis. <i>Circulation</i> , 2004, 110, 552-557.	1.6	157
60	Usefulness of Heart Rate to Predict Cardiac Events in Treated Patients With High-Risk Systemic Hypertension. <i>American Journal of Cardiology</i> , 2012, 109, 685-692.	1.6	157
61	Baroreflex Sensitivity and Its Evolution During the First Year After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 1988, 12, 629-636.	2.8	155
62	Comparison of Cardiovascular, Renal, and Humoral Effects of Acute Administration of Two Calcium Channel Blockers in Normotensive and Hypertensive Subjects. <i>Journal of Cardiovascular Pharmacology</i> , 1982, 4, S325.	1.9	153
63	Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. <i>Journal of Hypertension</i> , 2002, 20, 1307-1314.	0.5	153
64	Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis. <i>Stroke</i> , 2004, 35, 2807-2812.	2.0	153
65	Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The study on cognition and prognosis in the elderly (SCOPE). <i>Journal of the American College of Cardiology</i> , 2004, 44, 1175-1180.	2.8	152
66	Effects of blood pressure lowering on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2014, 32, 2296-2304.	0.5	151
67	Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. <i>Journal of Hypertension</i> , 2001, 19, 1539-1545.	0.5	148
68	Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. <i>Journal of Hypertension</i> , 2006, 24, 1405-1412.	0.5	139
69	Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. <i>Journal of Hypertension</i> , 2006, 24, 2163-2168.	0.5	138
70	The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial. <i>Hypertension</i> , 2006, 48, 385-391.	2.7	138
71	AUTONOMIC HYPOTHALAMIC OUTBURSTS ELICITED BY CEREBELLAR STIMULATION. <i>Journal of Neurophysiology</i> , 1954, 17, 475-483.	1.8	137
72	Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. <i>Journal of Hypertension</i> , 2001, 19, 1149-1159.	0.5	135

#	ARTICLE	IF	CITATIONS
73	Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima-media thickness. <i>Journal of Hypertension</i> , 2000, 18, 197-201.	0.5	133
74	Visit-to-Visit Blood Pressure Variability, Carotid Atherosclerosis, and Cardiovascular Events in the European Lacidipine Study on Atherosclerosis. <i>Circulation</i> , 2012, 126, 569-578.	1.6	133
75	Randomized Controlled Trials of Blood Pressure Lowering in Hypertension. <i>Circulation Research</i> , 2015, 116, 1058-1073.	4.5	131
76	Ambulatory and Home Blood Pressure Normality in the Elderly. <i>Hypertension</i> , 1997, 30, 1-6.	2.7	131
77	Effects of blood pressure-lowering on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1321-1341.	0.5	123
78	Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study. <i>Journal of Hypertension</i> , 2005, 23, 2269-2276.	0.5	122
79	Antihypertensive treatment in patients with type-2 diabetes mellitus. <i>Journal of Hypertension</i> , 2002, 20, 2099-2110.	0.5	121
80	Baseline Values but Not Treatment-Induced Changes in Carotid Intima-Media Thickness Predict Incident Cardiovascular Events in Treated Hypertensive Patients. <i>Circulation</i> , 2009, 120, 1084-1090.	1.6	119
81	Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement. <i>Journal of Hypertension</i> , 2016, 34, 1665-1677.	0.5	118
82	White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next?. <i>Journal of Hypertension</i> , 1996, 14, 1049-1052.	0.5	117
83	Blood pressure control in Italy: results of recent surveys on hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1491-1498.	0.5	117
84	Lack of placebo effect on ambulatory blood pressure. <i>American Journal of Hypertension</i> , 1995, 8, 311-315.	2.0	116
85	Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. <i>European Heart Journal</i> , 2011, 32, 1500-1508.	2.2	116
86	Management of the hypertensive patient with elevated heart rate. <i>Journal of Hypertension</i> , 2016, 34, 813-821.	0.5	116
87	Specific Appearance of Sympathetic Cholinergic Vasodilatation in Muscles during Conditioned Movements. <i>Nature</i> , 1971, 232, 124-125.	27.8	112
88	Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles. <i>Journal of Hypertension</i> , 2003, 21, 797-804.	0.5	111
89	Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. <i>American Journal of Hypertension</i> , 2002, 15, 932-940.	2.0	109
90	The 1993 Guidelines for the Management of Mild Hypertension: Memorandum from a WHO/ISH Meeting. <i>Blood Pressure</i> , 1993, 2, 86-100.	1.5	108

#	ARTICLE	IF	CITATIONS
91	Impact of hypertension and antihypertensive treatment on organ damage. <i>American Journal of Cardiology</i> , 1999, 84, 18-24.	1.6	107
92	Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2002, 20, 1855-1864.	0.5	107
93	Effects of blood pressure lowering on outcome incidence in hypertension. <i>Journal of Hypertension</i> , 2014, 32, 2305-2314.	0.5	106
94	Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension. <i>Journal of Hypertension</i> , 2002, 20, 2293-2300.	0.5	105
95	Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. <i>Journal of Hypertension</i> , 2000, 18, 629-642.	0.5	103
96	Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. <i>Journal of Hypertension</i> , 2001, 19, 79-88.	0.5	102
97	Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome. <i>Journal of Hypertension</i> , 2005, 23, 875-882.	0.5	101
98	Systolic vs Diastolic Blood Pressure Control in the Hypertensive Patients of the PAMELA Population. <i>Archives of Internal Medicine</i> , 2002, 162, 582.	3.8	97
99	VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. <i>American Journal of Hypertension</i> , 2003, 16, 544-548.	2.0	97
100	Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. <i>European Heart Journal</i> , 2016, 37, 955-964.	2.2	95
101	Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. <i>Journal of Hypertension</i> , 1995, 13, 1105-1112.	0.5	92
102	Ambulatory Blood Pressure Monitoring in the Evaluation of Antihypertensive Treatment: Additional Information from a Large Data Base. <i>Blood Pressure</i> , 1995, 4, 148-156.	1.5	92
103	Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?. <i>Journal of Hypertension</i> , 2009, 27, 1509-1520.	0.5	91
104	Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1175-1180.	2.8	89
105	Definition of Kidney Dysfunction as a Cardiovascular Risk Factor<subtitled>Use of Urinary Albumin Excretion and Estimated Glomerular Filtration Rate</subtitled>. <i>Archives of Internal Medicine</i> , 2008, 168, 617.	3.8	89
106	Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. <i>Contemporary Clinical Trials</i> , 1998, 19, 370-390.	1.9	88
107	Latin American guidelines on hypertension*. <i>Journal of Hypertension</i> , 2009, 27, 905-922.	0.5	88
108	The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. <i>Journal of Hypertension</i> , 2004, 22, 1605-1612.	0.5	87

#	ARTICLE	IF	CITATIONS
109	Mechanisms of Renal Release of Renin by Electrical Stimulation of the Brainstem in the Cat. <i>Circulation Research</i> , 1974, 34, 425-434.	4.5	86
110	Patterns of hypertension management in Italy. <i>Journal of Hypertension</i> , 2000, 18, 1691-1699.	0.5	86
111	Control of blood pressure by carotid sinus baroreceptors in human beings. <i>American Journal of Cardiology</i> , 1979, 44, 895-902.	1.6	85
112	Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure. <i>Journal of Hypertension</i> , 2017, 35, 2150-2160.	0.5	84
113	Modification of arterial baroreflexes by captopril in essential hypertension. <i>American Journal of Cardiology</i> , 1982, 49, 1415-1419.	1.6	83
114	Prevalence and correlates of aortic root dilatation in patients with essential hypertension: relationship with cardiac and extracardiac target organ damage. <i>Journal of Hypertension</i> , 2006, 24, 573-580.	0.5	83
115	Relation of cardiovascular changes in fighting to emotion and exercise*. <i>Journal of Physiology</i> , 1971, 212, 321-335.	2.9	82
116	Pulse pressure and isolated systolic hypertension: Association with microalbuminuria. <i>Kidney International</i> , 2000, 58, 1211-1218.	5.2	82
117	Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial. <i>Blood Pressure</i> , 2001, 10, 83-91.	1.5	80
118	Hypertensive myocardial fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 20-23.	0.7	79
119	Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis. <i>Journal of Hypertension</i> , 2012, 30, 1241-1251.	0.5	79
120	Blood pressure control in Italy. <i>Journal of Hypertension</i> , 2012, 30, 1065-1074.	0.5	78
121	Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives?. <i>Journal of Human Hypertension</i> , 2009, 23, 728-734.	2.2	77
122	Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality. <i>Journal of Hypertension</i> , 2018, 36, 1622-1636.	0.5	77
123	Control of renin release: A review of experimental evidence and clinical implications. <i>American Journal of Cardiology</i> , 1976, 37, 675-691.	1.6	76
124	The Study on COgnition and Prognosis in the Elderly (SCOPE) â€œ Major CV events and stroke in subgroups of patients. <i>Blood Pressure</i> , 2005, 14, 31-37.	1.5	75
125	Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure â€œ meta-analyses of randomized trials. <i>Journal of Hypertension</i> , 2016, 34, 373-384.	0.5	75
126	Effects of blood-pressure-lowering treatment in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1921-1932.	0.5	74

#	ARTICLE	IF	CITATIONS
127	Retinal microvascular changes and target organ damage in untreated essential hypertensives. <i>Journal of Hypertension</i> , 2004, 22, 2095-2102.	0.5	72
128	Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients. <i>Journal of Hypertension</i> , 2006, 24, 647-653.	0.5	70
129	Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. <i>Journal of Hypertension</i> , 2007, 25, 2463-2470.	0.5	70
130	Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. <i>Blood Pressure</i> , 2004, 13, 17-32.	1.5	69
131	Effects of blood pressure lowering treatment in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1451-1463.	0.5	69
132	Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. <i>Journal of Hypertension</i> , 2007, 25, 1473-1479.	0.5	68
133	Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. <i>Journal of Hypertension</i> , 2002, 20, 1015-1022.	0.5	67
134	Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. <i>Journal of Hypertension</i> , 2008, 26, 357-367.	0.5	67
135	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. <i>PLoS Medicine</i> , 2018, 15, e1002538.	8.4	67
136	Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. <i>Journal of Hypertension</i> , 2002, 20, 2301-2307.	0.5	65
137	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. <i>Journal of Hypertension</i> , 2014, 32, 1888-1897.	0.5	65
138	Multiple risk factors in hypertension: results from the Gubbio Study. <i>Journal of Hypertension</i> , 1990, 8, S7-S12.	0.5	64
139	Cardiovascular Regulation during Sleep. , 1980, , 1-55.		63
140	Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-diadys study. <i>Journal of Hypertension</i> , 2007, 25, 2158-2167.	0.5	62
141	Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. <i>European Heart Journal</i> , 2010, 31, 2837-2840.	2.2	62
142	Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. <i>Journal of Hypertension</i> , 2013, 31, 223-238.	0.5	61
143	Protein intake and kidney function in the middle-age population: contrast between cross-sectional and longitudinal data. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1733-1740.	0.7	61
144	Isolated systolic hypertension in the young. <i>Journal of Hypertension</i> , 2018, 36, 1222-1236.	0.5	61

#	ARTICLE	IF	CITATIONS
145	Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. <i>International Journal of Cardiology</i> , 2014, 176, 219-226.	1.7	60
146	No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. <i>Blood Pressure</i> , 2016, 25, 83-92.	1.5	59
147	Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality. <i>Journal of Hypertension</i> , 2018, 36, 1637-1647.	0.5	59
148	Evidence-based medicine in hypertension: what type of evidence?. <i>Journal of Hypertension</i> , 2005, 23, 1113-1120.	0.5	58
149	Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. <i>Journal of Hypertension</i> , 2007, 25, 1087-1094.	0.5	58
150	24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. <i>Journal of Hypertension</i> , 1997, 15, 1511-1518.	0.5	57
151	Left ventricular and carotid structure in untreated, uncomplicated essential hypertension: results from the Assessment Prognostic Risk Observational Survey (APROS). <i>Journal of Human Hypertension</i> , 2004, 18, 891-896.	2.2	57
152	Neural and Non-neural Mechanisms influencing Circulation during Sleep. <i>Nature</i> , 1969, 223, 184-185.	27.8	56
153	Left ventricular concentric remodelling and carotid structural changes in essential hypertension. <i>Journal of Hypertension</i> , 1996, 14, 1441-1446.	0.5	56
154	Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study. <i>Journal of Hypertension</i> , 2001, 19, 819-825.	0.5	56
155	Effects of angiotensin and angiotensin blockade on coronary circulation and coronary reserve. <i>American Journal of Medicine</i> , 1988, 84, 55-60.	1.5	54
156	Age and Target Organ Damage in Essential Hypertension: Role of the Metabolic Syndrome. <i>American Journal of Hypertension</i> , 2007, 20, 296-303.	2.0	54
157	Summary of prazosin lipid studies. <i>American Journal of Medicine</i> , 1984, 76, 122-124.	1.5	53
158	Efficacy, Tolerability, and Impact on Quality of Life of Long-Term Treatment with Manidipine or Amlodipine in Patients with Essential Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, 642-650.	1.9	53
159	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. <i>Journal of Hypertension</i> , 2009, 27, 673-679.	0.5	53
160	Prevalence of home blood pressure measurement among selected hypertensive patients: Results of a multicenter survey from six hospital outpatient hypertension clinics in Italy. <i>Blood Pressure</i> , 2005, 14, 251-256.	1.5	52
161	Postischemic Left Ventricular Dysfunction is Abolished by Alpha-Adrenergic Blocking Agents 11This study was supported by institutional funds from the University of Milan (MURST 60%). Hewlett Packard Germany provided the echocardiographic equipment used in this study; Hewlett Packard Italiana S.P.A. provided technologic assistance in the acquisition of the data presented here.. <i>Journal of the American College of Cardiology</i> , 1998, 31, 992-1001.	2.8	51
162	Low Muscular Mass and Overestimation of Microalbuminuria by Urinary Albumin/Creatinine Ratio. <i>Hypertension</i> , 2006, 47, 56-61.	2.7	51

#	ARTICLE	IF	CITATIONS
163	Effect of Long-Term Antihypertensive Treatment on White-Coat Hypertension. <i>Hypertension</i> , 2014, 64, 1388-1398.	2.7	51
164	Transient but not sustained blood pressure increments by occupational noise. An ambulatory blood pressure measurement study. <i>Journal of Hypertension</i> , 2001, 19, 1021-1027.	0.5	50
165	Lack of Association Between Serum Uric Acid and Organ Damage in a Never-Treated Essential Hypertensive Population at Low Prevalence of Hyperuricemia. <i>American Journal of Hypertension</i> , 2007, 20, 678-685.	2.0	50
166	Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) â€“ A review. <i>Blood Pressure</i> , 2006, 15, 71-79.	1.5	49
167	Cardiac and carotid structure in patients with established hypertension and white-coat hypertension. <i>Journal of Hypertension</i> , 1995, 13, 1707-1711.	0.5	48
168	Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. <i>BMJ: British Medical Journal</i> , 2010, 340, c1197-c1197.	2.3	48
169	Serum uric acid for short term prediction of cardiovascular disease incidence in the Gubbio population Study. <i>Acta Cardiologica</i> , 2001, 56, 243-251.	0.9	47
170	Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005, 15, 426-440.	2.6	47
171	Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. <i>Journal of Hypertension</i> , 2006, 24, 1671-1677.	0.5	47
172	SPRINT Blood Pressure. <i>Hypertension</i> , 2017, 69, 15-19.	2.7	45
173	Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. <i>Journal of Hypertension</i> , 1998, 16, 1831-1838.	0.5	42
174	Impact of the Gubbio population study on community control of blood pressure and hypertension. <i>Journal of Hypertension</i> , 2001, 19, 843-850.	0.5	42
175	Longing for clinical excellence. <i>Journal of Hypertension</i> , 2012, 30, 660-668.	0.5	42
176	Role of calcium antagonists in systemic hypertension. <i>American Journal of Cardiology</i> , 1987, 59, B130-B136.	1.6	41
177	Goals of Antihypertensive Treatment: Prevention of Cardiovascular Events and Prevention of Organ Damage. <i>Blood Pressure</i> , 1992, 1, 205-211.	1.5	41
178	Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. <i>Journal of Hypertension</i> , 2010, 28, 2342-2350.	0.5	41
179	Defining ambulatory and home blood pressure normality: further considerations based on data from the PAMELA study. <i>Journal of Hypertension</i> , 2001, 19, 995-999.	0.5	40
180	Reproducibility of dipping/nondipping pattern in untreated essential hypertensive patients: impact of sex and age. <i>Blood Pressure Monitoring</i> , 2007, 12, 101-106.	0.8	39

#	ARTICLE	IF	CITATIONS
181	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. <i>Journal of Hypertension</i> , 2014, 32, 1741-1750.	0.5	39
182	Cardiovascular Changes during Preparation for Fighting Behaviour in the Cat. <i>Nature</i> , 1968, 220, 1239-1240.	27.8	38
183	Non-dipper treated hypertensive patients do not have increased cardiac structural alterations. <i>Cardiovascular Ultrasound</i> , 2003, 1, 1.	1.6	38
184	Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment. <i>Journal of Hypertension</i> , 2004, 22, 1201-1212.	0.5	37
185	Ambulatory blood pressure, target organ damage and aortic root size in never-treated essential hypertensive patients. <i>Journal of Human Hypertension</i> , 2007, 21, 531-538.	2.2	37
186	Is retinal arteriolar-venular ratio associated with cardiac and extracardiac organ damage in essential hypertension?. <i>Journal of Hypertension</i> , 2009, 27, 1277-1283.	0.5	36
187	Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. <i>Journal of Hypertension</i> , 2012, 30, 67-74.	0.5	36
188	Serum uric acid and eGFR_CKDEPI differently predict long-term cardiovascular events and all causes of deaths in a residential cohort. <i>International Journal of Cardiology</i> , 2014, 171, 361-367.	1.7	36
189	Effects of Celiprolol on Reflex Control of the Cardiovascular System in Essential Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1986, 8, S67-S74.	1.9	35
190	Central and Reflex Regulation of Sympathetic Vasoconstrictor Activity to Limb Muscles during Desynchronized Sleep in the Cat. <i>Circulation Research</i> , 1974, 35, 625-635.	4.5	34
191	Impact of nocturnal fall in blood pressure on early cardiovascular changes in essential hypertension. <i>Journal of Hypertension</i> , 1999, 17, 1339-1344.	0.5	34
192	MASKed-unconTrolled hypERTension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. <i>BMJ Open</i> , 2018, 8, e021038.	1.9	33
193	Treatment Perspectives in Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 24, S61.	1.9	33
194	Cognitive Function and Health-Related Quality of Life in Elderly Patients with Hypertension - Baseline Data from the Study on COgnition and Prognosis in the Elderly (SCOPE). <i>Blood Pressure</i> , 2002, 11, 157-165.	1.5	32
195	International Society of Hypertension (ISH). <i>Journal of Hypertension</i> , 2003, 21, 649-650.	0.5	32
196	Indexation Criteria of Ventricular Mass and Predictive Role of Blood Pressure and Body Composition. <i>American Journal of Hypertension</i> , 2005, 18, 1282-1287.	2.0	32
197	Improving cardiovascular risk stratification in essential hypertensive patients by indexing left ventricular mass to height ^{2.7} . <i>Journal of Hypertension</i> , 2009, 27, 2465-2471.	0.5	32
198	Similarities and differences in structural and functional changes of left ventricle and carotid arteries in young borderline hypertensives and in athletes. <i>Journal of Hypertension</i> , 1996, 14, 759-764.	0.5	31

#	ARTICLE	IF	CITATIONS
199	Red blood cell count in short-term prediction of cardiovascular disease incidence in the Gubbio population Study. <i>Acta Cardiologica</i> , 2002, 57, 177-185.	0.9	31
200	Prevalence and clinical correlates of right ventricular hypertrophy in essential hypertension. <i>Journal of Hypertension</i> , 2009, 27, 854-860.	0.5	31
201	Overview of cardiovascular reflexes in hypertension. <i>American Journal of Cardiology</i> , 1979, 44, 912-918.	1.6	30
202	Arterial baroreceptor control of blood pressure in man. <i>Journal of the Autonomic Nervous System</i> , 1984, 11, 115-124.	1.9	30
203	Hyperlipidemia in the hypertensive patient. <i>American Journal of Medicine</i> , 1994, 96, S3-S8.	1.5	30
204	Choice of antihypertensive drugs in the European Society of Hypertension—European Society of Cardiology guidelines: specific indications rather than ranking for general usage. <i>Journal of Hypertension</i> , 2008, 26, 164-168.	0.5	30
205	Prevalence of target organ damage in treated hypertensive patients. <i>Journal of Hypertension</i> , 2000, 18, 803-809.	0.5	29
206	Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. <i>Journal of Hypertension</i> , 2019, 37, 1126-1147.	0.5	29
207	Cardiovascular risk stratification in hypertensive patients: Impact of echocardiography and carotid ultrasonography. <i>Journal of Hypertension</i> , 2001, 19, 375-380.	0.5	28
208	High prevalence of retinal vascular changes in never-treated essential hypertensives: an inter- and intra-observer reproducibility study with non-mydratic retinography. <i>Blood Pressure</i> , 2004, 13, 25-30.	1.5	28
209	Quality control of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis. <i>Journal of Hypertension</i> , 2005, 23, 1047-1054.	0.5	28
210	Studies on Left Ventricular Hypertrophy Regression in Arterial Hypertension: A Clear Message for the Clinician?. <i>American Journal of Hypertension</i> , 2008, 21, 458-463.	2.0	28
211	Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring. <i>American Journal of Cardiology</i> , 1992, 70, D60-D66.	1.6	27
212	Blood pressure control in a hypertension hospital clinic. <i>Journal of Hypertension</i> , 1999, 17, 835-841.	0.5	27
213	Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (l)per(tensione and (dia)bete study. <i>Journal of Hypertension</i> , 2008, 26, 1801-1808.	0.5	27
214	Body mass index, nocturnal fall in blood pressure and organ damage in untreated essential hypertensive patients. <i>Blood Pressure Monitoring</i> , 2008, 13, 318-324.	0.8	27
215	Cardiac hypertrophy as a target of antihypertensive therapy. <i>Nature Reviews Cardiology</i> , 2010, 7, 66-67.	13.7	27
216	Editors' Corner: Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. <i>Journal of Hypertension</i> , 1996, 14, 809-811.	0.5	26

#	ARTICLE	IF	CITATIONS
217	Prevalence of episodes of ST-segment depression among mild-to-moderate hypertensive patients in northern Italy. <i>Journal of Hypertension</i> , 1998, 16, 681-688.	0.5	26
218	Ambulatory blood pressure, target organ damage and left atrial size in never-treated essential hypertensive individuals. <i>Journal of Hypertension</i> , 2005, 23, 1589-1595.	0.5	26
219	Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). <i>Journal of Hypertension</i> , 2005, 23, 1091-1098.	0.5	26
220	Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. <i>Journal of Hypertension</i> , 2016, 34, 393-396.	0.5	26
221	Impairment of the arterial baroreflex during symptomatic and silent myocardial ischemia in humans. <i>Journal of the American College of Cardiology</i> , 1993, 22, 1866-1872.	2.8	25
222	Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. <i>Journal of Hypertension</i> , 2005, 23, 1099-1106.	0.5	25
223	Cardiovascular outcomes in hypertensive patients. <i>Journal of Hypertension</i> , 2012, 30, 2213-2222.	0.5	25
224	Differences between office and ambulatory blood pressures in children and adolescents attending a hospital hypertension clinic. <i>Journal of Hypertension</i> , 2013, 31, 2165-2175.	0.5	25
225	Cohort Profile: The Gubbio Population Study. <i>International Journal of Epidemiology</i> , 2014, 43, 713-720.	1.9	25
226	Antihypertensive Treatment and Blood Pressure in Diabetic and Nondiabetic Patients: The lower, the better?. <i>Diabetes Care</i> , 2011, 34, S304-S307.	8.6	24
227	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). <i>Revista Española De Cardiología</i> , 2013, 66, 880.e1-880.e64.	1.2	24
228	Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study. <i>European Heart Journal</i> , 2014, 35, 299-306.	2.2	24
229	Relation of urinary albumin excretion to coronary heart disease and low renal function: Role of blood pressure. <i>Kidney International</i> , 2004, 65, 2290-2297.	5.2	23
230	Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure. <i>Journal of Hypertension</i> , 2017, 35, 2138-2149.	0.5	23
231	Cardiovascular Disease and the Kidney: An Epidemiologic Overview. <i>Journal of Cardiovascular Pharmacology</i> , 1999, 33, S1-S6.	1.9	23
232	Methyldopa and neural control of circulation in essential hypertension. <i>American Journal of Cardiology</i> , 1980, 45, 1237-1243.	1.6	22
233	Hemodynamic Factors Changing Blood Flow Velocity Waveform and Profile in Normal Human Brachial Artery. <i>Angiology</i> , 1985, 36, 1-8.	1.8	22
234	Ambulatory blood pressure monitoring. <i>Journal of Hypertension</i> , 1996, 14, S61-S68.	0.5	22

#	ARTICLE	IF	CITATIONS
235	Emerging data on calcium-channel blockers: The COHORT study. <i>Clinical Cardiology</i> , 2003, 26, 17-20.	1.8	22
236	Left ventricular hypertrophy in treated hypertensive patients with good blood pressure control outside the clinic, but poor clinic blood pressure control. <i>Journal of Hypertension</i> , 2003, 21, 1575-1581.	0.5	22
237	The Antiatherogenic Effects of Antihypertensive Drugs: Experimental and Clinical Evidence. <i>Clinical and Experimental Hypertension</i> , 1992, 14, 307-331.	0.3	21
238	On the importance of estimating renal function for cardiovascular risk assessment. <i>Journal of Hypertension</i> , 2004, 22, 1635-1639.	0.5	21
239	Antihypertensive Efficacy of Manidipine and Enalapril in Hypertensive Diabetic Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 926-931.	1.9	21
240	Cardiovascular and renal effects of single administration of three different doses of isradipine in hypertensive patients. <i>American Journal of Medicine</i> , 1989, 86, 65-66.	1.5	20
241	Cardiopulmonary receptor and arterial baroreceptor reflexes after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1992, 69, 873-878.	1.6	20
242	Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA). <i>Journal of Hypertension</i> , 1995, 13, S35-S39.	0.5	20
243	Cardiovascular risk stratification according to the 2003 ESH&ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria. <i>Blood Pressure</i> , 2004, 13, 142-151.	1.5	20
244	How reliable is isolated clinical hypertension defined by a single 24-h ambulatory blood pressure monitoring?. <i>Journal of Hypertension</i> , 2007, 25, 315-320.	0.5	20
245	Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention. <i>Vascular Health and Risk Management</i> , 2008, 4, 67-73.	2.3	20
246	Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans. <i>American Heart Journal</i> , 1989, 117, 740-745.	2.7	19
247	Woven left coronary artery disease. <i>American Journal of Cardiology</i> , 1995, 75, 311-312.	1.6	19
248	Assessment of carotid plaque composition in hypertensive patients by ultrasonic tissue characterization: a validation study. <i>Journal of Hypertension</i> , 2002, 20, 1589-1596.	0.5	19
249	Zofenopril plus Hydrochlorothiazide. <i>Drugs</i> , 2006, 66, 1107-1115.	10.9	19
250	Twenty-year cardiovascular and all-cause mortality trends and changes in cardiovascular risk factors in Gubbio, Italy: the role of blood pressure changes. <i>Journal of Hypertension</i> , 2009, 27, 266-274.	0.5	19
251	Hypertension Guidelines: Is It Time to Reappraise Blood Pressure Thresholds and Targets?. <i>Hypertension</i> , 2016, 68, 257-262.	2.7	19
252	Proteomic-Biostatistic Integrated Approach for Finding the Underlying Molecular Determinants of Hypertension in Human Plasma. <i>Hypertension</i> , 2017, 70, 412-419.	2.7	19

#	ARTICLE	IF	CITATIONS
253	Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol. <i>American Heart Journal</i> , 1984, 108, 1078-1083.	2.7	18
254	A Re-examination of Stepped-Care. <i>Journal of Cardiovascular Pharmacology</i> , 1985, 7, S126-S131.	1.9	18
255	Latin American consensus on diabetes mellitus and hypertension. <i>Journal of Hypertension</i> , 2004, 22, 2229-2241.	0.5	18
256	Afferent Pathways of Neural Reno-Renal Reflexes Controlling Sodium and Water Excretion in the Cat. <i>Journal of Hypertension</i> , 1987, 5, 417-424.	0.5	17
257	Evaluation of the antihypertensive effect of celiprolol by ambulatory blood pressure monitoring. <i>American Journal of Cardiology</i> , 1988, 61, C27-C33.	1.6	17
258	How much should blood pressure be lowered? The problem of the J-shaped curve. <i>Journal of Hypertension</i> , 1989, 7, S338-348.	0.5	17
259	Guidelines for the management of hypertension: the world Health organisation/International society of Hypertension View. <i>Journal of Hypertension</i> , 1995, 13, S119-S122.	0.5	17
260	Nocturnal non-dipping pattern in untreated hypertensives at different cardiovascular risk according to the 2003 ESH/ESC guidelines. <i>Blood Pressure</i> , 2006, 15, 37-44.	1.5	17
261	Left and right ventricular structural changes in obese hypertensives. <i>Blood Pressure</i> , 2009, 18, 23-29.	1.5	17
262	Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients. <i>Journal of Hypertension</i> , 2012, 30, 1468-1477.	0.5	17
263	Population-based dose-response curve of glomerular filtration rate to dietary protein intake. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1156-1162.	0.7	17
264	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. <i>Current Problems in Cardiology</i> , 2017, 42, 198-225.	2.4	17
265	Renal Effects of Felodipine in Hypertension. <i>Drugs</i> , 1987, 34, 59-66.	10.9	16
266	Echocardiographic and Ultrasonographic Evaluation of Cardiac and Vascular Hypertrophy in Patients with Essential Hypertension. <i>Cardiology</i> , 1992, 80, 305-311.	1.4	16
267	Is the nocturnal fall in blood pressure reduced in essential hypertensive patients with metabolic syndrome?. <i>Blood Pressure</i> , 2004, 13, 230-235.	1.5	16
268	Metabolic syndrome score and ambulatory blood pressure in untreated essential hypertension. <i>Blood Pressure Monitoring</i> , 2005, 10, 175-180.	0.8	16
269	Metabolic syndrome and multiple organ damage in essential hypertension. <i>Blood Pressure</i> , 2008, 17, 195-203.	1.5	16
270	Prevalence and correlates of multiple organ damage in a never-treated hypertensive population: role of ambulatory blood pressure. <i>Blood Pressure Monitoring</i> , 2008, 13, 7-13.	0.8	16

#	ARTICLE	IF	CITATIONS
271	Electrical Carotid Baroreceptor Stimulation in Resistant Hypertension. <i>Hypertension</i> , 2010, 55, 607-609.	2.7	16
272	Wars, War Games, and Dead Bodies on the Battlefield. <i>Stroke</i> , 2011, 42, 2722-2724.	2.0	16
273	Treatment of hypertension in the elderly: Effects on blood pressure, heart rate, and physical fitness. <i>American Journal of Medicine</i> , 1991, 90, S12-S13.	1.5	15
274	Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study. <i>Journal of Hypertension</i> , 2005, 23, 1203-1209.	0.5	15
275	Metabolic syndrome and target organ damage: role of blood pressure. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 731-743.	1.5	15
276	Meta-analyses: first-rank evidence or second-hand information?. <i>Nature Reviews Cardiology</i> , 2011, 8, 249-251.	13.7	15
277	Typical and atypical coronary heart disease deaths and their different relationships with risk factors. The Gubbio residential cohort Study. <i>International Journal of Cardiology</i> , 2014, 173, 300-304.	1.7	15
278	PROLONGED INTRA-ARTERIAL BLOOD-PRESSURE RECORDING IN DIAGNOSIS OF PHĀ†CHROMOCYTOMA. <i>Lancet, The</i> , 1979, 314, 1193-1194.	13.7	14
279	Renal hemodynamic effects of dopexamine hydrochloride. <i>American Journal of Cardiology</i> , 1988, 62, 53C-36C.	1.6	14
280	Right ventricular wall thickness and function in hypertensive patients with and without left ventricular hypertrophy: echo-Doppler study. <i>Journal of Hypertension</i> , 1989, 7, S108-109.	0.5	14
281	New year, new challenges. <i>Journal of Hypertension</i> , 2003, 21, 1-2.	0.5	14
282	Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study. <i>Journal of Hypertension</i> , 2010, 28, 2016-2025.	0.5	14
283	Antihypertensive treatment is not a risk factor for major cardiovascular events in the Gubbio residential cohort study. <i>Journal of Hypertension</i> , 2015, 33, 736-744.	0.5	14
284	Participation of the Renin-angiotensin System in the Maintenance of Blood Pressure During Changes in Posture in Patients with Essential Hypertension. <i>Journal of Hypertension</i> , 1985, 3, 55-61.	0.5	13
285	Looking back on three years of Editorship. <i>Journal of Hypertension</i> , 1998, 16, 1.	0.5	13
286	The antiatherogenic effects of antihypertensive treatment: Trials completed and ongoing. <i>Current Hypertension Reports</i> , 2001, 3, 350-359.	3.5	13
287	Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA). <i>Journal of Hypertension</i> , 2005, 23, 557-562.	0.5	13
288	Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril. <i>Journal of Hypertension</i> , 2009, 27, 626-632.	0.5	13

#	ARTICLE	IF	CITATIONS
289	Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy. <i>Journal of Hypertension</i> , 2012, 30, 2202-2212.	0.5	13
290	What format for hypertension guidelines. <i>Journal of Hypertension</i> , 2014, 32, 1-2.	0.5	13
291	Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. <i>Journal of Hypertension</i> , 2014, 32, 1551-1552.	0.5	13
292	Different effects of antihypertensive treatment on office and ambulatory blood pressure. <i>Journal of Hypertension</i> , 2019, 37, 467-475.	0.5	13
293	Natriuretic Effects of Calcium Antagonists. <i>Drugs</i> , 1990, 40, 15-21.	10.9	12
294	23 ELSA, European Lacidipine Study on Atherosclerosis. <i>Journal of Hypertension</i> , 1993, 11, S405.	0.5	12
295	Evaluation of organ damage in hypertension. <i>Journal of Hypertension</i> , 1993, 11, 875-882.	0.5	12
296	Trials investigating the anti-atherosclerotic effects of antihypertensive drugs. <i>Journal of Hypertension</i> , 1996, 14, S77-S81.	0.5	12
297	Relationship between plasma insulin and left ventricular mass in normotensive participants of the Gubbio Study. <i>Clinical Endocrinology</i> , 2003, 58, 316-322.	2.4	12
298	The ALLHAT trial. <i>Journal of Hypertension</i> , 2003, 21, 223.	0.5	12
299	Hypertension: which aspects of hypertension should we impact on and how?. <i>Journal of Hypertension</i> , 2006, 24, S2-S5.	0.5	12
300	Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial. <i>Blood Pressure</i> , 2008, 17, 170-177.	1.5	12
301	The Hyper-Pract Study: A multicentre survey on the accuracy of the echocardiographic assessment of hypertensive left ventricular hypertrophy in clinical practice. <i>Blood Pressure</i> , 2008, 17, 124-128.	1.5	12
302	GuÃas Latinoamericanas de HipertensiÃ³n Arterial. <i>Revista Chilena De CardiologÃa</i> , 2010, 29, .	0.0	12
303	Relationships of different types of event to cardiovascular death in trials of antihypertensive treatment. <i>Journal of Hypertension</i> , 2014, 32, 495-508.	0.5	12
304	Effects of Reversible Renal Denervation on Haemodynamic and Excretory Functions of the Ipsilateral and Contralateral Kidney in the Cat. <i>Journal of Hypertension</i> , 1986, 4, 181-188.	0.5	11
305	Current position of calcium antagonists in hypertension. <i>Journal of Hypertension</i> , 1996, 14, S11-S15.	0.5	11
306	Role of the renal nerves in the control of renin synthesis during different sodium intakes in the rat. <i>Journal of Hypertension</i> , 2001, 19, 1271-1277.	0.5	11

#	ARTICLE	IF	CITATIONS
307	One hundred years of auscultatory blood pressure. <i>Journal of Hypertension</i> , 2005, 23, 1-2.	0.5	11
308	New evidence and critical reappraisal of available evidence. <i>Journal of Hypertension</i> , 2015, 33, 1-2.	0.5	11
309	Best antihypertensive strategies to improve blood pressure control in Latin America. <i>Journal of Hypertension</i> , 2018, 36, 208-220.	0.5	11
310	Treatment goals in hypertension. <i>American Journal of Medicine</i> , 1984, 76, 1-3.	1.5	10
311	Calcium Antagonists and Neural Control of Circulation in Essential Hypertension. <i>Journal of Hypertension</i> , 1987, 5, S49-S55.	0.5	10
312	Goals of Antihypertensive Treatment and Planning of Therapeutic Trials. <i>American Journal of Hypertension</i> , 1994, 7, 13S-15S.	2.0	10
313	Results of Antihypertensive Treatment Trials in the Elderly. <i>The American Journal of Geriatric Cardiology</i> , 2002, 11, 41-48.	0.6	10
314	Left ventricular hypertrophy regression with antihypertensive treatment: focus on candesartan. <i>Blood Pressure</i> , 2003, 12, 5-15.	1.5	10
315	Evidence and wisdom: recommendations for forthcoming guidelines. <i>Journal of Hypertension</i> , 2011, 29, 1-3.	0.5	10
316	Hemodynamic and Humoral Effects of Chronic Treatment with the Neutral Endopeptidase Inhibitor SCH 42495 in Spontaneously Hypertensive Rats. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 703-708.	1.9	9
317	Coping with the challenges of the next four years. <i>Journal of Hypertension</i> , 2002, 20, 1-2.	0.5	9
318	Costs of implementing recommendations on hypertension management given in recent guidelines. <i>Journal of Hypertension</i> , 2003, 21, 2207-2209.	0.5	9
319	Do we over treat mild hypertension?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1121-1126.	1.8	9
320	Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes. , 2007, , 211-218.		9
321	190 Ambulatory and home blood pressure reference values. <i>Journal of Hypertension</i> , 1993, 11, S481.	0.5	8
322	Short- and Long-Term Perspectives of Antihypertensive Therapy An Introduction. <i>American Journal of Hypertension</i> , 1993, 6, 2S-5S.	2.0	8
323	Clinical Advantages of Lipophilic Dihydropyridines. <i>Blood Pressure</i> , 1998, 7, 23-26.	1.5	8
324	Management of hypertension in patients with left ventricular hypertrophy. <i>Current Hypertension Reports</i> , 2007, 9, 498-505.	3.5	8

#	ARTICLE	IF	CITATIONS
325	Has Antihypertensive Treatment Prevented Vascular Disease or Vascular Events?. Journal of Cardiovascular Pharmacology, 1992, 19, 1-5.	1.9	8
326	Discussion on the Natriuretic Effect of Calcium Antagonists. Journal of Cardiovascular Pharmacology, 1987, 10, S161-S164.	1.9	7
327	Interactions between the sympathetic nervous system and atrial natriuretic factor in the control of renal functions. Journal of Hypertension, 1990, 8, 703-710.	0.5	7
328	The 24-Hour Efficacy of a New Once-Daily Formulation of Nifedipine. Drugs, 1994, 48, 23-31.	10.9	7
329	Effects of a reversible α -nephrectomy TM on renal sympathetic activity and blood pressure in the rat. Journal of Hypertension, 2000, 18, 1277-1287.	0.5	7
330	Neuronal nitric oxide synthase and renin stimulation by sodium deprivation are dependent on the renal nerves. Journal of Hypertension, 2002, 20, 2039-2045.	0.5	7
331	Editing a scientific journal: problems and challenges. Journal of Hypertension, 2008, 26, 1-3.	0.5	7
332	Challenges in hypertension. Journal of Hypertension, 2014, 32, 451-453.	0.5	7
333	Heritability of blood pressure through latent curve trajectories in families from the Gubbio population study. Journal of Hypertension, 2014, 32, 2179-2187.	0.5	7
334	Central and Reflex Control of Renin Release. Progress in Brain Research, 1977, 47, 397-407.	1.4	6
335	Relation between the hypotensive and renin-suppressing activities of alpha methyl dopa in hypertensive patients. American Journal of Cardiology, 1977, 40, 762-767.	1.6	6
336	Left Ventricular Diastolic Function in Athletes and Borderline Hypertensives with Mild Cardiac Hypertrophy. Cardiology, 1991, 78, 278-281.	1.4	6
337	Regulation of vasopressin release in moderately severe essential hypertension. Clinical Autonomic Research, 1991, 1, 109-114.	2.5	6
338	Antihypertensive therapy. Journal of Hypertension, 1995, 13, 1522-1528.	0.5	6
339	Editors' corner: debating the value of absolute versus relative risk. Journal of Hypertension, 1996, 14, 681.	0.5	6
340	Risk of major gastrointestinal bleeding with aspirin. Lancet, The, 1999, 353, 149-150.	18.7	6
341	Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients. Blood Pressure, 2006, 15, 107-115.	1.5	6
342	Editor's corner. Journal of Hypertension, 2013, 31, 1-2.	0.5	6

#	ARTICLE	IF	CITATIONS
343	Osmotic indices and kidney concentrating activity: population-based data on correlates and prognostic power. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 274-283.	0.7	6
344	Emotion and the Cardiovascular System in the Cat. <i>Novartis Foundation Symposium</i> , 1972, 8, 201-223.	1.1	6
345	Calcium Antagonists and Responsiveness of the Adrenal Glands to Aldosterone-Releasing Stimuli in Hypertensive Patients. <i>Journal of Hypertension</i> , 1987, 5, S119-S122.	0.5	5
346	Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VAST) trial.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, S8.	1.7	5
347	The dilemma of placebo controlled studies: scientific evidence, guidelines, ethics and regulatory recommendations. <i>Journal of Hypertension</i> , 2009, 27, 1-2.	0.5	5
348	What should be learnt about the management of obstructive sleep apnea in hypertension?. <i>Journal of Hypertension</i> , 2012, 30, 669-670.	0.5	5
349	Information, discernment and learning. <i>Journal of Hypertension</i> , 2012, 30, 1-2.	0.5	5
350	Vascular and parenchymal lesions along with enhanced neurogenesis characterize the brain of asymptomatic stroke-prone spontaneous hypertensive rats. <i>Journal of Hypertension</i> , 2013, 31, 1618-1628.	0.5	5
351	Factors influencing blood pressure levels. <i>Journal of Hypertension</i> , 2015, 33, 1497-1498.	0.5	5
352	Hypertension-related mortality and morbidity. <i>Journal of Hypertension</i> , 2015, 33, 1979-1980.	0.5	5
353	From risk factors to treatment of hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1-2.	0.5	5
354	Lower or higher blood-pressure targets for high-risk patients?. <i>Nature Reviews Cardiology</i> , 2016, 13, 637-638.	13.7	5
355	Physiological Versus Pathological Hypertrophy. <i>Advances in Experimental Medicine and Biology</i> , 1997, , 145-158.	1.6	5
356	Reflex and Brain Stem Inhibition of Sham Rage Behaviour. <i>Progress in Brain Research</i> , 1968, 22, 195-205.	1.4	4
357	The renin-angiotensin system and the heart. <i>American Journal of Medicine</i> , 1988, 84, 1-2.	1.5	4
358	Cardiac and Carotid Structure in Arterial Hypertension and in Hypertrophic Cardiomyopathy. <i>Cardiology</i> , 1995, 86, 211-216.	1.4	4
359	Antihypertensive therapy: safety and efficacy of drugs and publications. <i>Journal of Hypertension</i> , 1996, 14, 273-275.	0.5	4
360	Safety Profile of Lacidipine. <i>Drugs</i> , 1999, 57, 27-29.	10.9	4

#	ARTICLE	IF	CITATIONS
361	Carotid atherosclerosis and cardiovascular risk stratification: Role and cost-effectiveness of echo-Doppler examination in untreated essential hypertensives. <i>Blood Pressure</i> , 2006, 15, 333-339.	1.5	4
362	The 24h blood pressure-R interval relation in ambulatory monitoring. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2008, 139, 68-77.	2.8	4
363	Estimating the glomerular filtration rate in the Spanish working population. <i>Journal of Hypertension</i> , 2014, 32, 1970-1978.	0.5	4
364	White Coat Hypertension. , 2015, , .		4
365	Estimation of metabolic syndrome heritability in three large populations including full pedigree and genomic information. <i>Human Genetics</i> , 2019, 138, 739-748.	3.8	4
366	Alterations of Cardiovascular Reflexes in Hypertension. <i>Clinical and Experimental Hypertension</i> , 1980, 2, 451-464.	1.3	3
367	Acute hypotensive and renin-stimulating actions of captopril before and during treatment with a beta-blocking drug. <i>American Journal of Cardiology</i> , 1982, 49, 1564-1565.	1.6	3
368	The effects of Mianserin therapy on plasma renin activity in depressed patients. <i>Biological Psychiatry</i> , 1986, 21, 1331-1334.	1.3	3
369	Effects of dilevalol on forearm circulation in essential hypertension. <i>American Journal of Cardiology</i> , 1989, 63, 121-124.	1.6	3
370	Value of Echocardiographic and Ambulatory Blood Pressure Monitoring in Hypertension. <i>Clinical and Experimental Hypertension</i> , 1989, 11, 869-886.	0.3	3
371	First-Line Treatment in Hypertension. <i>Drugs</i> , 1990, 39, 71-75.	10.9	3
372	Safety of the calcium antagonist lacidipine evaluated from a phase III/IV trial database. <i>Journal of Hypertension</i> , 1996, 14, S15-S20.	0.5	3
373	Effects of antihypertensive treatment on vasopressin secretion and on its osmoregulation in moderate hypertension. <i>Journal of Hypertension</i> , 1997, 15, 1277-1283.	0.5	3
374	Electrophysiological evidence of ipsilateral reno-renal reflexes in the cat. <i>Journal of the Autonomic Nervous System</i> , 1997, 65, 45-48.	1.9	3
375	Clinical Advantages of Lipophilic Dihydropyridines. <i>Blood Pressure</i> , 1998, 7, 23-26.	1.5	3
376	Searching for information from unreported trials - amnesty for the past and prospective meta-analyses for the future. <i>Journal of Hypertension</i> , 1998, 16, 125.	0.5	3
377	Factors influencing acute ischaemia-induced renal hypertension in rats. <i>Journal of Hypertension</i> , 2002, 20, 2453-2463.	0.5	3
378	FEVER study: a trial further supporting the concept of a blood pressure-independent stroke protective effect by dihydropyridines. <i>Journal of Hypertension</i> , 2006, 24, 1215-1216.	0.5	3

#	ARTICLE	IF	CITATIONS
379	Reply to Blood pressure target in chronic kidney disease. <i>Journal of Hypertension</i> , 2013, 31, 2321-2322.	0.5	3
380	Antihypertensive Treatment. <i>Journal of Cardiovascular Pharmacology</i> , 1991, 17, S48-50.	1.9	3
381	Patients with Prehypertension “ Do we have Enough Evidence to Treat them?. <i>Current Vascular Pharmacology</i> , 2014, 12, 586-597.	1.7	3
382	Vascular complications in hypertension: The VHAS study. <i>Cardiovascular Drugs and Therapy</i> , 1995, 9, 529-531.	2.6	2
383	Cardiac and renal damage in the elderly hypertensive.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, S16.	1.7	2
384	Where is hypertension research going?. <i>Journal of Hypertension</i> , 2007, 25, 1-3.	0.5	2
385	Clinical practice and guidelines in Europe for the treatment of hypertension, with a focus on patients with diabetes mellitus. <i>Clinical Therapeutics</i> , 2007, 29, S44-S53.	2.5	2
386	Issues in the development of new combinations of blood pressure lowering drugs. <i>Journal of Hypertension</i> , 2010, 28, 2494-2496.	0.5	2
387	Agreement within Europe about antihypertensive treatment and education “ results from the European Society of Hypertension questionnaire. <i>Journal of Hypertension</i> , 2010, 28, 1593-1594.	0.5	2
388	Foreword. <i>Journal of Hypertension</i> , 2011, 29, S1.	0.5	2
389	Calcium Channel Blockers in Hypertension. , 2013, , 204-218.		2
390	Measuring interarm blood pressure differences in diabetes. <i>Nature Reviews Endocrinology</i> , 2014, 10, 387-388.	9.6	2
391	Obesity and other aspects of hypertension. <i>Journal of Hypertension</i> , 2015, 33, 423-424.	0.5	2
392	Risk of Coronary Disease and Coronary Complications by Neural and Psychological Factors. <i>Advances in Experimental Medicine and Biology</i> , 1975, 63, 323-335.	1.6	2
393	White Coat Hypertension: The History of the Irresistible, Resistible Ascent of a Misnomer. , 2015, , 137-147.		2
394	A Non-Invasive Index of Leg Arterial Perfusion Pressure During Walking, Derived From Cutaneous Toe Temperature. <i>Angiology</i> , 1985, 36, 528-540.	1.8	1
395	Effect on resting blood pressure and blood pressure homeostasis of short-term administration of the alpha1-adrenergic receptor antagonist, trimazosin, in hypertension. <i>Cardiovascular Drugs and Therapy</i> , 1988, 1, 535-542.	2.6	1
396	Overview and Perspectives of Antihypertensive Treatment. <i>Drugs</i> , 1990, 40, 85-91.	10.9	1

#	ARTICLE	IF	CITATIONS
397	Target Blood Pressure in Elderly Hypertensive Patients: How Low Should You Go?. Blood Pressure, 2000, 9, 7-11.	1.5	1
398	The Journal of Hypertension: web visits and citations. Journal of Hypertension, 2005, 23, 1281-1283.	0.5	1
399	Nebivolol in Hypertension and Chronic Heart Failure. Drugs, 2006, 66, 1410.	10.9	1
400	Reading and citing from the Journal of Hypertension: an article listed as the top cited medical paper in 2003â€”2005. Journal of Hypertension, 2006, 24, 1219-1222.	0.5	1
401	Reading and citing from the Journal of Hypertension. Journal of Hypertension, 2007, 25, 1319-1322.	0.5	1
402	Calcium Channel Blockers in Hypertension. , 2007, , 268-285.		1
403	Reading and citing from the Journal of Hypertension. Journal of Hypertension, 2008, 26, 1271-1274.	0.5	1
404	Introduction: Reducing cardiovascular risk: ONTARGET â€” a new standard in cardiovascular protection. Journal of Hypertension, 2009, 27, S1.	0.5	1
405	Antihypertensive therapy: from 2003 to 2013 and beyond. Expert Review of Cardiovascular Therapy, 2013, 11, 1443-1446.	1.5	1
406	What to look for in the current issue?. Journal of Hypertension, 2013, 31, 431-432.	0.5	1
407	Contributions to debated problems. Journal of Hypertension, 2013, 31, 637-638.	0.5	1
408	Salt, inflammation, pathophysiological mechanisms, and organ damage in hypertension. Journal of Hypertension, 2014, 32, 205-206.	0.5	1
409	Predictive, mechanistic, and therapeutic studies on hypertension and cardiovascular morbidity and mortality. Journal of Hypertension, 2014, 32, 1549-1550.	0.5	1
410	From pathophysiology to therapeutic interventions. Journal of Hypertension, 2014, 32, 703-705.	0.5	1
411	Challenges of hypertension and hypertension treatment. Journal of Hypertension, 2014, 32, 1917-1918.	0.5	1
412	From dietary factors to drug adherence. Journal of Hypertension, 2015, 33, 895-896.	0.5	1
413	Lifestyle and therapeutic interventions for hypertension. Journal of Hypertension, 2015, 33, 2183-2184.	0.5	1
414	Role of socio-economic factors, blood pressure measurement, and therapeutic strategies in hypertension. Journal of Hypertension, 2015, 33, 193-194.	0.5	1

#	ARTICLE	IF	CITATIONS
415	Obesity, diabetes, and antidiabetic treatment. <i>Journal of Hypertension</i> , 2016, 34, 165-166.	0.5	1
416	Benefits and Risks of Antihypertensive Treatment. <i>Circulation</i> , 2018, 137, 144-147.	1.6	1
417	Residual Risk in Treated Hypertension. , 2012, , 309-321.		1
418	Excretory Responses to Renal Nerve Stimulation During Inhibition of Neutral Metalloendopeptidase and Angiotensin-Converting Enzyme in the Rat. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 28, 665-671.	1.9	1
419	Effects of Adenosine Receptor Agonists on Efferent Renal Nerve Activity in Anesthetized Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 189-194.	1.9	1
420	The VALUE Trial. , 2005, , 366-375.		1
421	Regulation of circulation by carotid sinus, aortic and cardiopulmonary receptors. <i>Journal of Neural Transmission</i> , 1966, 28, 197-211.	2.8	0
422	Editorial comment ACE inhibitors and cardioprotection. <i>Cardiovascular Drugs and Therapy</i> , 1989, 3, 855-857.	2.6	0
423	New European studies on atherosclerosis in hypertension. <i>International Journal of Cardiovascular Imaging</i> , 1995, 11, 115-118.	0.6	0
424	Updating recommendations for prevention of coronary heart disease. <i>Journal of Hypertension</i> , 1998, 16, 1401-1402.	0.5	0
425	Perindopril/Indapamide. <i>Drugs</i> , 1999, 58, 303-304.	10.9	0
426	Cardiac, renal and vascular complications in the diabetic patient. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2000, 1, 21-24.	1.7	0
427	John Chalmers's Festschrift. <i>Journal of Hypertension</i> , 2002, 20, 1031.	0.5	0
428	News, Reminiscences and Perspectives: a new section of the <i>Journal of Hypertension</i> . <i>Journal of Hypertension</i> , 2002, 20, 1033.	0.5	0
429	Translating worldwide calcium-channel blocker experience into clinical practice. <i>Clinical Cardiology</i> , 2003, 26, 1-2.	1.8	0
430	The value of long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. <i>American Journal of Hypertension</i> , 2003, 16, A12.	2.0	0
431	Design of the Syst-Eur trial and Syst-Eur Phase 2. <i>Journal of Hypertension</i> , 2004, 22, 1631-1632.	0.5	0
432	The José L. Rodicio Festschrift. <i>Journal of Hypertension</i> , 2005, 23, 1111.	0.5	0

#	ARTICLE	IF	CITATIONS
433	On the state of the Journal. Journal of Hypertension, 2006, 24, 1.	0.5	0
434	Introduction. Journal of Hypertension, 2007, 25, S1-S2.	0.5	0
435	Reliability of Blood Pressure Patterns Defined by a Single 24-Hour Ambulatory Blood Pressure Monitoring: The Case of the Dipping/Non Dipping and Isolated Clinic Hypertension. Current Hypertension Reviews, 2007, 3, 89-92.	0.9	0
436	Introduction: avancÃ©es rÃ©centes dans la prÃ©vention des maladies cardiovasculaires chez le patient diabÃ©tique. Journal of Hypertension, 2008, 26, S1-S2.	0.5	0
437	Introduction: Advances in the prevention of cardiovascular disease in patients with diabetes. Journal of Hypertension, 2008, 26, S1-S2.	0.5	0
438	An outlook on the content of this journal issue. Journal of Hypertension, 2013, 31, 1059-1060.	0.5	0
439	Facets of hypertension research. Journal of Hypertension, 2013, 31, 2107-2108.	0.5	0
440	Investigation clues for prognosis, diagnosis and therapeutic strategies. Journal of Hypertension, 2013, 31, 2327-2328.	0.5	0
441	Ambulatory blood pressure monitoring, arterial function and other problems concerning hypertension. Journal of Hypertension, 2013, 31, 1729-1730.	0.5	0
442	Guidelines, organ damage, diagnostic procedures and treatment. Journal of Hypertension, 2013, 31, 1923-1924.	0.5	0
443	What really matters is not what the authors meant to say, it is how their work is read. Journal of Hypertension, 2013, 31, 1499-1501.	0.5	0
444	Contributions to management of hypertension from papers in the current issue. Journal of Hypertension, 2013, 31, 845-847.	0.5	0
445	Blood pressure and opera. Journal of Hypertension, 2013, 31, 427.	0.5	0
446	Editor's Corner. Journal of Hypertension, 2013, 31, 221-222.	0.5	0
447	Guidelines and research upon which guidelines are founded. Journal of Hypertension, 2013, 31, 1279-1280.	0.5	0
448	Investigating multiple aspects of blood pressure control. Journal of Hypertension, 2014, 32, 1157-1158.	0.5	0
449	Predictive medicine, pathophysiology and therapeutics. Journal of Hypertension, 2014, 32, 1725-1726.	0.5	0
450	A look at differences. Journal of Hypertension, 2014, 32, 949-950.	0.5	0

#	ARTICLE	IF	CITATIONS
451	Recommendations for practice and mechanistic investigations. <i>Journal of Hypertension</i> , 2014, 32, 1357-1358.	0.5	0
452	Hypertension-related organ damage and cardiovascular risk. <i>Journal of Hypertension</i> , 2014, 32, 2107-2108.	0.5	0
453	Focus on clinical problems. <i>Journal of Hypertension</i> , 2014, 32, 2283-2284.	0.5	0
454	Studying arterial wall in hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1719-1720.	0.5	0
455	Large and small vessel disease and other aspects of hypertension. <i>Journal of Hypertension</i> , 2015, 33, 2371-2372.	0.5	0
456	Dietary and metabolic aspects of hypertension and hypertension-related organ damage. <i>Journal of Hypertension</i> , 2015, 33, 1117-1118.	0.5	0
457	From the pathophysiological to the epidemiological approach to hypertension research. <i>Journal of Hypertension</i> , 2015, 33, 667-668.	0.5	0
458	From blood pressure measurement to antihypertensive treatment. <i>Journal of Hypertension</i> , 2015, 33, 1319-1320.	0.5	0
459	Lercanidipine in worldwide usage. <i>Current Medical Research and Opinion</i> , 2015, 31, 161-162.	1.9	0
460	Prognostic, diagnostic, and therapeutic advances in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 811-812.	0.5	0
461	Prediction, diagnosis and treatment of hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1025-1026.	0.5	0
462	From pregnancy to childhood and adulthood. <i>Journal of Hypertension</i> , 2016, 34, 1235-1236.	0.5	0
463	Challenges of antihypertensive treatment. <i>Journal of Hypertension</i> , 2016, 34, 1449-1450.	0.5	0
464	Reply. <i>Journal of Hypertension</i> , 2016, 34, 2103-2104.	0.5	0
465	Prediction and prevention of hypertension-related events. <i>Journal of Hypertension</i> , 2016, 34, 591-592.	0.5	0
466	Dietary, clinical and therapeutic aspects of hypertension. <i>Journal of Hypertension</i> , 2016, 34, 371-372.	0.5	0
467	Guidelines, position studies, and blood vessel research. <i>Journal of Hypertension</i> , 2017, 35, 1527-1528.	0.5	0
468	What Is New and What Is Different in Recent Guidelines on Antihypertensive Treatment? Looking Forward to Guidelines Reappraisal. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , 839-851.	0.1	0

#	ARTICLE	IF	CITATIONS
469	Blood Pressure-Lowering Treatment and the Prevention of Heart Failure: Differences and Similarities of Antihypertensive Drug Classes. Updates in Hypertension and Cardiovascular Protection, 2019, , 285-298.	0.1	0
470	Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension, 2001, 19, 2106.	0.5	0
471	The 2003 Guidelines for the Management of Hypertension of the European Society of Hypertension and European Society of Cardiology. , 2007, , 1177-1184.		0
472	Arterial Baroreflexes in Normotensive and Hypertensive Man. Developments in Cardiovascular Medicine, 1982, , 34-56.	0.1	0
473	Are There Markers for the Physiopathology of Essential Hypertension?. , 1984, , 3-12.		0
474	Arterial Baroreflexes in Human Beings. Developments in Cardiovascular Medicine, 1984, , 190-206.	0.1	0
475	Baroreceptor mechanisms and the control of vascular resistance. Developments in Cardiovascular Medicine, 1989, , 349-361.	0.1	0
476	RESIDUAL RISK AND RESISTANCE TO THE BENEFITS OF ANTIHYPERTENSIVE TREATMENT. , 2014, , 543-552.		0
477	White Coat Hypertension: To Treat or Not to Treat. , 2015, , 123-135.		0
478	From inflammation to renal denervation in hypertension research. Journal of Hypertension, 2016, 34, 2301-2302.	0.5	0